Renaissance Technologies
PYXS icon

Renaissance Technologies’s Pyxis Oncology PYXS Stock Holding History

Renaissance Technologies’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.3M Buy
888,680
+160,300
+22% +$242K ﹤0.01% 2132
2025
Q4 		$838K Buy
728,380
+152,044
+26% +$536K ﹤0.01% 2369
2025
Q3 		$1.28M Buy
576,336
+158,514
+38% +$228K ﹤0.01% 2356
2025
Q2 		$460K Sell
417,822
-164,314
-28% -$185K ﹤0.01% 2876
2025
Q1 		$570K Buy
582,136
+288,782
+98% +$385K ﹤0.01% 2689
2024
Q4 		$458K Buy
293,354
+133,018
+83% +$384K ﹤0.01% 2883
2024
Q3 		$588K Buy
160,336
+63,400
+65% +$222K ﹤0.01% 2710
2024
Q2 		$321K Sell
96,936
-51,064
-35% -$215K ﹤0.01% 2884
2024
Q1 		$630K Sell
148,000
-216,150
-59% -$909K ﹤0.01% 2770
2023
Q4 		$655K Buy
364,150
+147,899
+68% +$253K ﹤0.01% 2650
2023
Q3 		$430K Sell
216,251
-36,978
-15% -$85.7K ﹤0.01% 2780
2023
Q2 		$648K Buy
253,229
+159,029
+169% +$504K ﹤0.01% 2735
2023
Q1 		$378K Buy
94,200
+10,600
+13% +$21.2K ﹤0.01% 3011
2022
Q4 		$112K Sell
83,600
-45,202
-35% -$67.8K ﹤0.01% 3579
2022
Q3 		$254K Buy
128,802
+53,431
+71% +$140K ﹤0.01% 3276
2022
Q2 		$179K Buy
+75,371
New +$201K ﹤0.01% 3690

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

Renaissance Technologies's PYXS Position: Q1 2026 in Review

Renaissance Technologies increased its Pyxis Oncology (PYXS) stake by 22% in Q1 2026, buying an estimated $242K and bringing the position to 888,680 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2132.

Renaissance Technologies first reported a position in PYXS in Q2 2022 and has held it in 16 quarters since. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Renaissance Technologies held 888,680 shares of Pyxis Oncology worth $1.3M as of Q1 2026.
  • Renaissance Technologies bought 160,300 Pyxis Oncology shares in Q1 2026, an estimated $242K.
  • Pyxis Oncology made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2132 holding.
  • Renaissance Technologies first reported a position in Pyxis Oncology in Q2 2022 and has held it in 16 quarters since.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.